Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended December 31, 2024
Business Overview: A medical technology company focused on non-invasive testing solutions. Operations are divided into two segments: the commercially available Intelligent Fingerprinting Products (IFPG) segment, which accounts for 100% of revenue, and the development-stage Biosensor Platform Technology (BPT) segment. The company recently submitted a 510(k) premarket notification to the FDA for its drug screening system.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $607,494 | $1,479,781 |
| Gross Profit | $223,113 | $569,914 |
| Gross Margin | 36.73% | 38.51% |
| Net Loss (Attributable to INBS) | $(2,249,470) | $(4,935,103) |
| Net Loss Per Share (Basic/Diluted) | $(0.50) | $(1.18) |
| Cash and Cash Equivalents (Dec 31, 2024) | $2,242,209 | |
| Working Capital Deficit | $(341,243) | |
| Accumulated Deficit | $(56,899,435) |
Government Support Income: $133,640 (3 months) and $259,768 (6 months), primarily from R&D tax refunds and grants.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 20.5% year-over-year for the three months ended Dec 31, 2024, and 5.2% for the six-month period. This was driven by instability in the construction sector, leading to lower sales of readers (hardware).
- Margin Expansion: Despite lower revenue, gross profit margins improved significantly (from 26.08% to 36.73% for the quarter). Management attributes this to a strategic shift toward selling high-margin consumable cartridges (approx. 89.58% contribution margin) versus readers (approx. 65.94%).
- Increased Operating Expenses: Development and regulatory approval expenses surged 45.5% for the quarter and 221.8% for the six-month period compared to 2023, driven by in-house R&D staff and clinical study costs for the FDA 510(k) submission.
- Cash Burn: Net cash used in operating activities was $4.71 million for the six months ended Dec 31, 2024, compared to $4.18 million in the prior year period.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Cash on hand ($2.24 million) is deemed insufficient to fund the current operating plan without additional financing.
- Capital Raising: The company is utilizing an At-The-Market (ATM) offering agreement to raise up to $3.0 million. Approximately $676,619 was raised under this agreement between September and December 2024. Subsequent to the period end, an additional $787,835 was raised through February 11, 2025.
- Grant Contingency: The company holds a liability of $2,299,644 related to an Australian government grant for a manufacturing facility. The company has only completed 4 of 8 milestones. If the remaining milestones are not met by the March 28, 2025 deadline, the company will be required to refund certain amounts.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, citing a lack of documented policies, insufficient review procedures, and limited accounting personnel.
- Regulatory Progress: The company successfully completed a method comparison clinical study and submitted its 510(k) application to the FDA on December 18, 2024.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of current cash reserves ($2.24M) against the burn rate and the timeline for FDA clearance to determine if additional equity dilution is imminent.
- Grant Milestones: Monitor the status of the Australian government grant milestones with a March 28, 2025 deadline to assess the risk of a potential $2.3M refund liability.
- Revenue Mix: Confirm the sustainability of the improved gross margins by tracking the ratio of cartridge sales to reader sales in upcoming quarters.
- Internal Control Remediation: Review progress on the remediation plan for material weaknesses in financial reporting controls to ensure future financial statement reliability.
- FDA Timeline: Track the status of the 510(k) submission, as US market entry is critical for long-term revenue growth.